Medtronic Stents    
Login  


ACS & AMI
Angiomyogenesis & Cell Therapy
Carotid Interventions
Imaging
Complex Coronary Interventions
Chronic Total Occlusion
Drug-Eluting Stents
Emerging Devices & Innovative Therapies
Nurse & Tech Corner
Peripheral Interventions
Vulnerable Plaque
Workshop with the FDA


Poll Archives
 
Start Date: 9/7/2010 End Date:10/7/2010
How the results of the Current OASIS 7 Trial impact your practice?
More use of Clopidogrel 75 mg BID for 7 days
42.86 %
More use of Prasugrel
21.43 %
No Change
35.71 %


Start Date: 8/23/2010 End Date:9/23/2010
What is the preferred approach for percutaneous mitral valve repair?
Annuloplasty
32.50 %
Edge to Edge
37.50 %
Mitral Valve Replacement
17.50 %
None of the above
12.50 %


Start Date: 8/9/2010 End Date:9/1/2010
Do you believe that the FDA regulatory requirements for approval of new devices for interventional cardiology are:
Just about right
21.74 %
Too strict and delayes introduction of devices to the US market
69.57 %
Too easy and impose risks for patients
8.70 %


Start Date: 7/26/2010 End Date:8/26/2010
How many cardiology journals do you read each month?
None
5.80 %
One
7.25 %
Two
36.23 %
Three
14.49 %
More than three
36.23 %


Start Date: 7/12/2010 End Date:7/26/2010
Are you currently using the Syntax score to determine revascularization strategy?
Yes
38.03 %
No
61.97 %


Start Date: 6/28/2010 End Date:8/15/2010
Which test is currently used in your institution for responsiveness of antiplatelet therapy?
Genetic
3.03 %
Platelet reactivity
27.27 %
Both
9.09 %
None
60.61 %


Start Date: 6/14/2010 End Date:7/14/2010
What will be the use of fully biodegradable stents once they approved for marketing?
Workhorse stent
38.10 %
Niche product
36.51 %
No role in coronary arteries
6.35 %
Only for patients who cannot take Plavix
19.05 %


Start Date: 5/26/2010 End Date:6/26/2010
Do you believe that OCT will replace IVUS?
Yes
40.14 %
No
59.86 %


Start Date: 5/10/2010 End Date:6/20/2010
What is your prediction of the results of the Resolute All Comers study  compared with Resolute versus Xience V, which will be presented at EuroPCR 2010?
Resolute is superior
13.53 %
XIENCE V is superior
48.12 %
No difference between Resolute and XIENCE V
38.35 %


Start Date: 5/3/2010 End Date:5/30/2010
Do you believe that there is a specific DES that is associated with better results in diabetic patients?
Yes
67.92 %
No
32.08 %


Start Date: 4/19/2010 End Date:5/19/2010
Do you believe that there are advantages for DES with bioabsorbable polymer over a DES with biocompatible durable polymer?
Yes
69.88 %
No
30.12 %


Start Date: 4/5/2010 End Date:4/30/2010
How will the health care bill impact your practice?
No major changes
17.07 %
Significantly less reimbursement
39.02 %
Improve quality of care
14.63 %
Reduce quality of care
29.27 %


Start Date: 3/15/2010 End Date:4/15/2010
Are the results from the EVEREST II Trial sufficient to approve the MITRALCLIP for patients with mitral regurgitation for commercial marketing in the US? 
Yes, for the majority of patients with MR
9.72 %
No, need more data and long term follow-up to support approval
52.78 %
Yes, for selected patients with MR
37.50 %


Start Date: 3/1/2010 End Date:3/15/2010
How will the results of the CREST study impact the use of carotid stenting?
Increase the use of carotid stenting
40.00 %
Increase the use of carotid endarterectomy
10.00 %
No change
50.00 %


Start Date: 2/15/2010 End Date:3/15/2010
Among the following societies, which one represent best the interventional cardiology community?
ACC
17.48 %
SCAI
40.78 %
Both ACC and SCAI
20.39 %
Neither is doing enough
21.36 %


Start Date: 2/1/2010 End Date:2/26/2010
What is the main reason for not using Prasugrel for patients with ACS?
Fear from Bleeding
42.65 %
Don't have it in the Cath lab
17.65 %
Cost
11.76 %
Patients pre loaded with Clopidogrel
27.94 %


Start Date: 1/25/2010 End Date:2/25/2010
When you need to perform PCI to a second vessel what is your practice in relates to timing?
The same procedure if there are no renal impairment
60.53 %
In the same admission
18.42 %
In 4-6 weeks from the PCI to the primary vessel
21.05 %


Start Date: 1/11/2010 End Date:2/14/2010
What should be the primary endpoint for CABG versus PCI study for unprotected LM?
Death and MI
22.86 %
Death MI TVR
14.29 %
Death MI TVR and Stroke
62.86 %


Start Date: 12/21/2009 End Date:1/21/2010
Which of the studies published or presented in 2009 will make most impact in 2010?
FAME
26.42 %
PROTECT AF
1.89 %
SYNTAX
44.65 %
SPIRIT IV
10.06 %
PLATO
6.92 %
EARLY ACS
3.77 %
CURRENT OASIS 7
6.29 %


Start Date: 12/7/2009 End Date:12/30/2009
Which PFO should be closed?
All PFO
17.39 %
Only post stroke
57.97 %
Only post stroke and for migraine
24.64 %


Start Date: 11/23/2009 End Date:12/23/2009
How did the FDA warning in regards to an interaction between clopidogrel and the PPI will impact your practice?
No Change
53.45 %
Less use of PPI with clopidogrel
36.21 %
Less use of clopidogrel with PPI
1.72 %
More use of Prasugrel
8.62 %


Start Date: 11/16/2009 End Date:11/24/2009
Do you support performing elective PCI in hospitals without surgical backup?
Yes
56.10 %
No
43.90 %


Start Date: 11/2/2009 End Date:11/20/2009
Do you believe that there is sufficient evidence to change the guidelines in regards to PCI of unprotected LM?
Yes
62.50 %
No
37.50 %


Start Date: 10/19/2009 End Date:11/20/2009
How will the latest data from Current Oasis 7 change antiplatelet practice for patients with ACS?
No change
15.87 %
More use of 600 mg versus (300 mg) as a loading dose
34.92 %
More use of 600 mg and 150 mg for the first week after PCI
36.51 %
More use of Prasugrel
12.70 %


Start Date: 10/5/2009 End Date:10/29/2009
How will the recent data on FFR (FAME)and IVUS (PROSPECT) will change their use in the cath lab?
More FFR
23.91 %
More IVUS
13.04 %
More FFR and IVUS
31.52 %
Will not change much
31.52 %


Start Date: 9/23/2009 End Date:10/29/2009
Do you support the public option for healthcare reform?
Yes
60.00 %
No
40.00 %


Start Date: 9/14/2009 End Date:9/29/2009
What is your prediction to the results of SPIRIT IV: Xience V versus TAXUS Express?
XIENCE V superior for MACE
55.29 %
XIENCE V superior to TAXUS for TVF but non-inferior for TLR
14.12 %
XIENCE V non-inferior to TAXUS for MACE
30.59 %


Start Date: 8/31/2009 End Date:9/14/2009
What is the usage of FFR in your lab?
< 5%
65.60 %
< 10%
17.60 %
< 20%
7.20 %
> 20%
9.60 %


Start Date: 8/24/2009 End Date:9/8/2009
What is your prediction to the results of OASIS 7 study (higher loading dose (600 mg) and maintenance dose (150 mg daily) of Clopidogrel)?
Improved efficacy; no difference in bleeding
28.30 %
Improved efficacy but more bleeding
41.51 %
No difference in efficacy; no difference in bleeding
3.77 %
No difference in efficacy; but more bleeding
26.42 %


Start Date: 8/10/2009 End Date:8/26/2009
For patients with cardiogenic shock which device is more effective for hemodynamic support?
Impella
24.49 %
IABP
31.29 %
Tandem Heart
35.37 %
No major differences among the available devices
8.84 %


Start Date: 7/27/2009 End Date:8/12/2009
Will the use of DES increase with the approval of Prasugrel (Effient)?
Yes
44.74 %
No
55.26 %


Start Date: 7/13/2009 End Date:7/29/2009
How often will you use Prasugrel (Effient) for patients with acute MI?
>75%
25.00 %
50-75%
10.42 %
25-<50%
18.75 %
<25%
45.83 %


Start Date: 7/6/2009 End Date:7/13/2009
Should the guidelines for PCI for unprotected LM be changed from class III?
Yes, change to class IIA
34.43 %
Yes, change to class IIB
45.90 %
No, more studies are needed
19.67 %


Start Date: 6/22/2009 End Date:7/23/2009
Do you support the new health care plan?
Yes
38.30 %
No
61.70 %


Start Date: 6/15/2009 End Date:6/24/2009
What will be the impact of the BARI 2D study results on the revascularization volume in diabetic patients?
No Impact
37.10 %
Less CABG and PCI
20.97 %
Less PCI
29.03 %
Less CABG
12.90 %


Start Date: 6/8/2009 End Date:6/20/2009
Do you believe that proton pump inhibitors impacts platelet responsiveness?
No impact
16.67 %
Yes, but should not change the practice
40.91 %
Yes, but should not be prescribed to patients with DES on Plavix
42.42 %


Start Date: 5/26/2009 End Date:6/26/2009
Will the SYNTAX score be adopted by the interventional cardiology community?
Yes
59.78 %
No
25.70 %
I don't know what the SYNTAX score is.
14.53 %


Start Date: 5/18/2009 End Date:5/27/2009
Do you believe that DES with bioabsorbable polymers are safer when compared to DES with durable polymers?
Yes
66.67 %
No
33.33 %


Start Date: 5/11/2009 End Date:5/20/2009
What is the main reason not to use the radial approach?
Lack of knowledge/ training
32.58 %
Complex PCI
31.46 %
I feel more comfortable with femoral access
35.96 %


Start Date: 5/4/2009 End Date:5/13/2009
What is the most important feature that influences DES selection?
Deliverability
5.76 %
Safety
76.96 %
Efficacy
17.28 %


Start Date: 4/27/2009 End Date:5/5/2009
The FDA advisory panel voted 7 to 5 to recommend the approval of the Watchman LAA closure device. Do you agree?
Yes
58.00 %
No
42.00 %


Start Date: 4/20/2009 End Date:4/29/2009
Which pattern of days do you prefer for interventional cardiology meetings?
Sunday, Monday and Tuesday
40.00 %
Monday, Tuesday and Wednesday
10.77 %
Wednesday, Thursday and Friday
49.23 %


Start Date: 4/13/2009 End Date:4/22/2009
Should patients be loaded with high dose Statin prior to PCI (ARMYDA-RECAPTURE)?
Yes, in all patients
32.86 %
Only in elective patients
22.86 %
Need larger data to support this strategy
44.29 %


Start Date: 4/6/2009 End Date:4/14/2009
How frequently should radial access for PCI be used?
>50%
34.07 %
20% - 50%
19.26 %
<20%
46.67 %


Start Date: 3/30/2009 End Date:4/8/2009
Do you believe that the FDA will approve marketing the Watchman device for atrial appendage closure based on the PROTECT AF data?
Yes
52.56 %
No
47.44 %


Start Date: 3/23/2009 End Date:3/31/2009
Should all non-responsive patients post CPR undergo cooling protocol?
Yes
60.00 %
No
20.00 %
Not familiar with the data
20.00 %


Start Date: 3/16/2009 End Date:3/25/2009
Should live cases in interventional courses be regulated by FDA and CME?
Yes
40.91 %
No
59.09 %


Start Date: 3/9/2009 End Date:3/17/2009
For patients undergoing PCI with DES, should the Clopidogrel dose be routinely tailored based on responsiveness?
Yes
47.19 %
No
22.47 %
Only in high risk patients
30.34 %


Start Date: 3/2/2009 End Date:3/11/2009
Will you use the Syntax score to determine who should undergo PCI or CABG?
Yes
52.07 %
No
25.62 %
I am not familiar with the Syntax score
22.31 %


Start Date: 2/23/2009 End Date:3/3/2009
Do you believe that the second generation drug-eluting stents are associated with less stent thrombosis when compared with the first generation Cypher and Taxus?
Yes
56.83 %
No
43.17 %


Start Date: 2/16/2009 End Date:2/24/2009
Would you continue to come to the major cardiology and interventional cardiology meetings if CME was not provided?
Yes
60.00 %
No
40.00 %


Start Date: 2/9/2009 End Date:2/19/2009
Will Prasugrel replace Clopidogrel once approved by the FDA?
Yes, in the majority of the patients
37.76 %
No, it will only be used for high risk patients with stent thrombosis
47.45 %
Yes, in the hospital, but patients will be prescribed Plavix upon discharge
14.80 %


Start Date: 2/2/2009 End Date:2/9/2009
Do you agree with the proposed legislation that drug and medical device manufacturers would need to publicly disclose all physician payments and gifts exceeding $100?
Yes
54.42 %
No
45.58 %


Start Date: 1/26/2009 End Date:2/2/2009
How will the results of the FAME study impact your practice in the cath lab?
I will increase the use of FFR
59.78 %
I will avoid angioplasty in intermediate lesions
11.96 %
The results will not impact my practice
28.26 %


Start Date: 1/19/2009 End Date:1/26/2009
What are your thoughts regarding the PCI guidelines?
I am familiar and adhere to the guidelines
55.00 %
I am familiar but do not adhere to the guidelines
21.67 %
There are too many guidelines
13.33 %
I am not familiar with the guidelines
10.00 %


Start Date: 1/12/2009 End Date:1/19/2009
What is the main reason for premature Plavix cessation?
Cost
51.82 %
Bleeding
25.45 %
Lack of education
19.09 %
Patients on too many pills
3.64 %


Start Date: 1/5/2009 End Date:1/12/2009
Is there a shortage of interventional cardiologists in your area?
Yes
22.22 %
No
77.78 %


Start Date: 12/22/2008 End Date:1/6/2009
Which of the following studies presented in 2008 will make most impact on clinical practice in 2009?
Syntax
50.39 %
Horizon AMI
7.87 %
Sort Out III
7.09 %
Jupiter
25.20 %
Triton TIMI 38
9.45 %


Start Date: 12/15/2008 End Date:12/22/2008
Will OCT have a role in clinical practice?
Yes
47.76 %
No
19.40 %
Only as a research tool
32.84 %


Start Date: 12/8/2008 End Date:12/15/2008
When do you use vascular closure devices?
All diagnostic and PCI cases
20.29 %
Most PCI cases
28.99 %
In PCI but not frequently
50.72 %


Start Date: 12/1/2008 End Date:12/8/2008
Do live case demonstrations jeopardize patient safety?
Yes
42.50 %
No
57.50 %


Start Date: 11/24/2008 End Date:12/1/2008
How does the economic crisis impact the cath lab in your hospital?
More patients with normal coronaries
8.33 %
Reduction in volume
28.33 %
Pressure from the administration on cost saving
33.33 %
No impact
30.00 %


Start Date: 11/17/2008 End Date:11/24/2008
How will the JUPITER study results impact your practice?
Order more hsCRP levels on low risk patients
35.71 %
Prescribe more Crestor
10.00 %
Increase the use of statins not limited to Crestor
30.00 %
The study results will not impact my practice
24.29 %


Start Date: 11/10/2008 End Date:11/17/2008
Is there an application for the drug coated balloon?
Coronary use (ISR, bifurcation, de-novo)
12.36 %
Peripheral use (SFA, CLI)
10.11 %
Both coronary and peripheral
55.06 %
No future use
22.47 %


Start Date: 11/3/2008 End Date:11/10/2008
Should the Clopidogrel dose be adjusted based on testing for responsiveness?
Yes
48.54 %
No
16.50 %
Only for high risk patients for stent thrombosis
34.95 %


Start Date: 10/27/2008 End Date:11/3/2008
How often should IIB/IIIA inhibitors be used for primary PCI of patients with AMI?
> 50%
55.65 %
10% - 50%
24.35 %
< 10%
7.83 %
Only when a clot is visible
12.17 %


Start Date: 10/20/2008 End Date:10/27/2008
How will the results of the Horizons AMI study impact the use of DES for AMI?
The results will increase the use of DES for AMI
30.71 %
The results will decrease the use of DES for AMI
5.71 %
The results will not change anything
63.57 %


Start Date: 10/13/2008 End Date:10/20/2008
Whose health care plan do you favor?
Barack Obama
57.24 %
John McCain
22.07 %
Neither
20.69 %


Start Date: 10/6/2008 End Date:10/13/2008
What is your prediction as to the results of the HORIZION-AMI (Taxus (DES) vs. Express (BMS) in patients with STEMI) trial?
Taxus is superior to Express
47.44 %
Taxus is non-inferior to Express
17.95 %
TAXUS reduced TLR but was less safe than Express
34.62 %


Start Date: 9/29/2008 End Date:10/6/2008
In your practice, for what percentage of patients it is realistic to achieve door to balloon time < 90 minutes?
> 75%
41.41 %
50-75%
34.34 %
< 50%
24.24 %


Start Date: 9/22/2008 End Date:9/29/2008
Should the Advisory panel to the FDA recommend approval of Prasugrel for marketing?
Yes
75.00 %
No
25.00 %


Start Date: 9/15/2008 End Date:9/22/2008
How will the results of the SYNTAX study impact your practice on patients with multivessel disease and unprotected LM?
More CABG
18.56 %
More PCI with DES
39.18 %
Will not change
42.27 %


Start Date: 9/8/2008 End Date:9/14/2008
Do you believe that biodegradable polymers have an advantage in a DES?
Yes
37.14 %
No
62.86 %


Start Date: 9/1/2008 End Date:9/7/2008
Which of the following DES is the most effective for diabetic patients?
Cypher
12.38 %
Taxus
24.15 %
Endeavor
49.23 %
Xience V
8.36 %
No difference among these stents
5.88 %


Start Date: 8/25/2008 End Date:8/31/2008
Will the SYNTAX study meets its primary clinical endpoint?
Yes
52.31 %
No
32.31 %
Only for the LM group
15.38 %


Start Date: 8/18/2008 End Date:8/25/2008
What impact will the quality of life data from the COURAGE trial have on PCI volume?
The data will increase PCI volume
10.38 %
The data will decrease PCI volume
32.08 %
The data will not influence PCI volume
57.55 %


Start Date: 8/11/2008 End Date:8/20/2008
What is the primary stent that XIENCE V / PROMOUS replaced in your lab?
Cypher
34.17 %
Taxus
40.83 %
Endeavor
23.17 %
BMS
1.83 %


Start Date: 8/4/2008 End Date:8/10/2008
What could be the main role of drug eluting balloons in PCI?
No role in PCI
24.00 %
Treatment of in-stent restenosis
44.00 %
Denovo lesions with and without BMS
18.67 %
Peripheral application
13.33 %


Start Date: 7/28/2008 End Date:8/3/2008
What is the best approach for patients with diffuse DES in-stent restenosis?
Same DES
6.19 %
Another DES
53.61 %
Vascular Brachytherapy
15.46 %
CABG
24.74 %


Start Date: 7/21/2008 End Date:7/27/2008
How is your PCI volume compared to last year?
The same
22.89 %
More
42.17 %
Less
34.94 %


Start Date: 7/14/2008 End Date:7/20/2008
What is your preferred lipid lowering agent in 2008?
Lipitor
41.38 %
Crestor
32.41 %
Vytorin
6.21 %
Zocor
20.00 %


Start Date: 7/7/2008 End Date:7/13/2008
With the approval of Xience, which of the four available stents will be your workhorse stent?
Cypher
0.44 %
Taxus
0.43 %
Endeavor
61.42 %
Xience V/ Promus
37.71 %


Start Date: 6/30/2008 End Date:7/6/2008
With the approval of Endeavor and Xience V/Promus what will determine your DES selection?
Deliverability
3.00 %
Safety
73.03 %
Efficacy
19.85 %
Price
4.12 %


Start Date: 6/23/2008 End Date:6/29/2008
Which is your preferred hemodynamic support device for high risk PCI?
IABP
78.05 %
Impella
15.85 %
Tandem Heart
6.10 %


Start Date: 6/16/2008 End Date:6/22/2008
Which of the following societies best represents the field of interventional cardiology?
SCAI
46.09 %
ACC
16.52 %
Both
33.04 %
Neither
4.35 %


Start Date: 6/9/2008 End Date:6/15/2008
How many cardiology journals do you read per month?
None
12.26 %
One
14.15 %
Two
28.30 %
Three or more
45.28 %


Start Date: 6/2/2008 End Date:6/8/2008
What is the best method of assessing an intermediate lesion?
Fractional Flow Reserve (FFR)
59.29 %
Intravascular Ultrasound (IVUS)
24.78 %
Non Invasive Stress Test
15.93 %


Start Date: 5/26/2008 End Date:6/1/2008
What is your preferred anticoagulant in patients with STEMI undergoing primary PCI?
Bivalirudin alone
13.59 %
Bivalirudin and GpIIB/IIIA inhibitors
14.56 %
Heparin alone
12.62 %
Heparin and GpIIB/IIIA inhibitors
59.22 %


Start Date: 5/19/2008 End Date:5/25/2008
Which of the DES would you choose to use for your own family member?
Cypher
2.00 %
Taxus
1.15 %
Endeavor
75.69 %
XienceV/Promus
21.16 %


Start Date: 5/12/2008 End Date:5/18/2008
Do you see an increase in PCI for unprotected LM disease?
Yes
71.43 %
No
28.57 %


Start Date: 5/5/2008 End Date:5/11/2008
Do you beleive that PCI can be performed safely in hospitals without onsite CABG?
Yes
75.94 %
No
24.06 %


Start Date: 4/28/2008 End Date:5/4/2008
Who would you like to see win the Democratic nomination for President?
Hillary Clinton
43.05 %
Barak Obama
56.95 %


Start Date: 4/21/2008 End Date:4/27/2008
Which stent should patients with AMI get?
Bare metal stent
51.33 %
Drug eluting stent
48.67 %


Start Date: 4/14/2008 End Date:4/20/2008
Do you think that there is enough data to support FDA approval for Prasugrel?
Yes
56.94 %
No
43.06 %


Start Date: 4/7/2008 End Date:4/13/2008
In what configuration would you like to see the future i2 ACC /SCAI meetings?
Joint meeting during ACC
50.00 %
Joint meeting apart from the ACC
15.28 %
Two separate meetings at different venues
34.72 %


Start Date: 3/31/2008 End Date:4/6/2008
Do you believe that the ENDEAVOR STENT is safer than TAXUS or CYPHER
Yes
35.60 %
No
64.40 %


Start Date: 3/24/2008 End Date:3/30/2008
In which DES do you see more stent fractures?
Never see stent fractures
32.50 %
See more in Taxus
12.50 %
See more in Cypher
55.00 %


Start Date: 3/17/2008 End Date:3/23/2008
Which DES you prefer for diabetic patients?
Cypher
18.07 %
Taxus
57.83 %
Endeavor
15.66 %
Does not matter
8.43 %


Start Date: 3/10/2008 End Date:3/16/2008
Should high risk patients for DES thrombosis undergo routine evaluation for aspirin and plavix resistance?
Yes
64.13 %
No
35.87 %


Start Date: 3/3/2008 End Date:3/9/2008
Which reservoir do you prefer for a DES system?
Durable
26.47 %
Biodegradable
73.53 %


Start Date: 2/25/2008 End Date:3/2/2008
How often do you use distal protection devices for PCI of SVG?
> 90%
23.47 %
50 - 90%
26.53 %
< 50%
50.00 %


Start Date: 2/12/2008 End Date:2/24/2008
Do you believe that there is a rebound phenonmenon after cessation of clopidogrel?
Yes
67.61 %
No
32.39 %


Start Date: 2/4/2008 End Date:2/11/2008
Now that Endeavor has received FDA approval, how will you use Endeavor in the lab?
Replacing the other approved DES
35.51 %
Replacing BMS
27.10 %
Replacing both of the other DES and BMS
37.38 %


Start Date: 1/28/2008 End Date:2/3/2008
How will the latest NEJM publication comparing DES vs BMS for off-label use influence your practice?
Will not have an impact
50.72 %
Increase use of DES
34.78 %
Decrease use of DES
14.49 %


Start Date: 1/21/2008 End Date:1/27/2008
How did the results of the ENHANCE study impact your prescription volume of Vytorin?
It did not change
47.67 %
It decreased
44.19 %
I am not aware of the ENHANCE study
8.14 %


Start Date: 1/14/2008 End Date:1/20/2008
In the 2008 presidential race, which candidates have the best health care platform?
The Democratic candidates
56.36 %
The Republican candidates
43.64 %


Start Date: 1/7/2008 End Date:1/13/2008
Do you believe that lowering the price of DES will increase their use substantially?
Yes
51.20 %
No
48.80 %


Start Date: 12/24/2007 End Date:1/6/2008
Which of the following studies presented in 2007 will have the most impact on your clinical practice in 2008?
COURAGE
53.33 %
HORIZONS
9.63 %
ACUITY
4.44 %
SCHARR (Swedish DES registry)
11.85 %
ENDEAVOR IV
12.59 %
TRITON TIMI 38
8.15 %


Start Date: 12/17/2007 End Date:12/23/2007
What is your opinion on the AHA/ACC Guidelines for STEMI and NSTEMI?
The guidelines should only be a recommendation to guide therapy
78.43 %
They should be enforced with reimbursement only for those who adhere to them
21.57 %


Start Date: 12/10/2007 End Date:12/16/2007
Do you feel that imaging vulnerable plaque with virtual histology, OCT, or intravascular MRI will be clinically useful?
Yes
66.67 %
No
33.33 %


Start Date: 12/3/2007 End Date:12/9/2007
Do you agree that the one year data on the safety and efficacy of the new generation of DES is sufficient for approval for marketing?
Yes
40.38 %
No
59.62 %


Start Date: 11/26/2007 End Date:12/2/2007
Is there value in detecting a vulnerable plaque in coronary arteries using invasive imaging technology?
Yes
72.27 %
No
27.73 %


Start Date: 11/19/2007 End Date:11/25/2007
Do you believe that patients with positive exercise stress tests should be referred directly to cath or to 64 CT angiography?
Directly to cath; no need for CT
80.00 %
Directly to CT; cath if CT positive
20.00 %


Start Date: 11/12/2007 End Date:11/18/2007
What is the main reason for volume reduction in PCI?
Fear of Stent Thrombosis
25.24 %
The results of the COURAGE trial
32.04 %
Less restenosis with DES
24.27 %
More smoking cessation and optimal medical therapy
18.45 %


Start Date: 11/5/2007 End Date:11/11/2007
In TRITON TIMI 38 Prasugrel showed less cardiac mortality and stent thrombosis, but more death from bleeding. Would you like to see the drug approved for marketing by the FDA?
Yes
54.32 %
No
45.68 %


Start Date: 10/29/2007 End Date:11/4/2007
What is your opinion regarding PCI and its relation to gender?
Similar efficacy in women vs men
41.67 %
Similar efficacy but more bleeding in women
20.83 %
Better efficacy and safety in men
37.50 %


Start Date: 10/15/2007 End Date:10/28/2007
Do you feel comfortable using Bivalirudin as the primary thrombin inhibitor for patients with acute MI?
Yes
38.05 %
No
61.95 %


Start Date: 10/8/2007 End Date:10/14/2007
What do you think will happen to DES useage in 2008?
It will increase
46.23 %
It will decrease
23.58 %
It will not change
30.19 %


Start Date: 10/1/2007 End Date:10/7/2007
How will approval of Endeavor in the US impact the market share of DES and BMS?
Decrease use of BMS
9.35 %
Decrease use of Cypher
10.79 %
Decrease use of Taxus
12.23 %
Decrease use of Cypher and Taxus
25.18 %
Decrease use of all three
42.45 %


Start Date: 9/24/2007 End Date:9/30/2007
Do you see an increase in in-stent restenosis since you shifted from DES to BMS?
Yes
50.59 %
No
49.41 %


Start Date: 9/17/2007 End Date:9/23/2007
What is your impression following the latest published meta anlaysis of Cypher versus Taxus?
Cypher is superior to Taxus
32.57 %
Taxus is superior to Cypher
26.29 %
There are no significant differences between the two
41.14 %


Start Date: 9/10/2007 End Date:9/16/2007
Following the latest presentations on DES at the ESC 2007, what is your projection for the use of DES in 2008?
Will increase
40.00 %
Will decrease
18.00 %
Will not change
42.00 %


Start Date: 8/27/2007 End Date:9/9/2007
One year later, what do you think about presentations from ESC06 stating that DES is associated with higher mortality and MI compared to BMS?
The presentations were accurate
16.06 %
The presentations were misleading
20.44 %
The presentations were not accurate, but appropriately raised important issues
63.50 %


Start Date: 8/20/2007 End Date:8/26/2007
For low risk patients with UA/NSTEMI, what is your preferred treatment strategy?
Immediate (directly to the cath lab)
42.86 %
Conservative (with medical therapy first)
57.14 %


Start Date: 8/13/2007 End Date:8/19/2007
What is your preference for stent design in the treatment of bifurcation lesions?
A dedicated bifurcated stent design
26.37 %
A stent with an access to the branch
29.67 %
No need for a dedicated stent - most cases can be treat with conventional stents
43.96 %


Start Date: 8/6/2007 End Date:8/12/2007
What would you recommend to the FDA with regards to Rosiglitazone (Avandia) following the Circulatory Panel's recommendations?
To add a warning to the labeling of the drug
38.78 %
Wait for more trials before making any decision
48.98 %
Remove Rosiglitazone from the market
12.24 %


Start Date: 7/30/2007 End Date:8/5/2007
What needs to be done to increase PCI volume?
PCI volume will increase without any marketing
21.05 %
Target educational programs to internists and general practitioners
47.37 %
Target educational programs to patients directly
15.79 %
Explore new markets like peripheral intervention
15.79 %


Start Date: 7/23/2007 End Date:7/29/2007
What do you recommend for patients undergoing stenting for saphenous vein grafts > 3.5 mm?
DES
27.88 %
BMS
72.12 %


Start Date: 7/16/2007 End Date:7/22/2007
Do you believe that routine use of aspiration catheters in primary PCI impacts clinical outcomes?
Yes
41.67 %
No